AR064809A1 - Formas cristalinas - Google Patents
Formas cristalinasInfo
- Publication number
- AR064809A1 AR064809A1 ARP070105447A ARP070105447A AR064809A1 AR 064809 A1 AR064809 A1 AR 064809A1 AR P070105447 A ARP070105447 A AR P070105447A AR P070105447 A ARP070105447 A AR P070105447A AR 064809 A1 AR064809 A1 AR 064809A1
- Authority
- AR
- Argentina
- Prior art keywords
- degrees
- crystalline
- lngstroms
- theta
- analyzed
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 3
- 229910052802 copper Inorganic materials 0.000 abstract 3
- 239000010949 copper Substances 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 3
- -1 2-tert-butylphenyl Chemical group 0.000 abstract 2
- 239000005950 Oxamyl Substances 0.000 abstract 2
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente se refiere a formas cristalinas del acido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2', 3', 5', 6', -tetrafluorofenoxi)-4-oxopentanoico (véase la formula 1). Se refiere además a composiciones farmacéuticas que comprenden dichas formas cristalinas y a la utilizacion de dichas composiciones farmacéuticas y dichas formas cristalinas en el tratamiento de varias afecciones, particularmente en el tratamiento de la fibrosis hepática. Reivindicacion 1: una forma cristalina del acido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2', 3', 5', 6', -tetrafluorofenoxi)-4-oxopentanoico. Reivindicacion 2: una forma cristalina segun la reivindicacion 1, conocida como forma I, que comprende picos a 7,7, 14,1, 21,4, 26,6, y 29,4 grados dos theta (+- 0,1grados) cuando se analiza por difraccion de polvo por rayos X utilizando radiacion K-alfa1 del cobre (longitud de onda = 1,5406 Lngstroms).Reivindicacion 3. una forma cristalina segun la reivindicacion 1, conocida como forma II, que comprende picos a 14,5, 17,3, 22,5, 25,0, y 26,8 grados dos theta (+- 0,1 grados) cuando se analiza por difraccion de polvo por rayos X utilizando radiacion K-alfa1 del cobre (longitud de onda = 1,5406 Lngstroms).Reivindicacion 4: una forma cristalina segun la reivindicacion 1, conocida como forma III, que comprende un pico a 7,2 grados dos theta (+- 0,1 grados) cuando se analiza por difraccion de polvo por rayos X utilizando radiacion K-alfa1 del cobre (longitud de onda = 1,5406 Lngstroms).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86874806P | 2006-12-06 | 2006-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064809A1 true AR064809A1 (es) | 2009-04-29 |
Family
ID=39205161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105447A AR064809A1 (es) | 2006-12-06 | 2007-12-05 | Formas cristalinas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7692038B2 (es) |
| EP (1) | EP2091910B1 (es) |
| JP (1) | JP5495787B2 (es) |
| KR (1) | KR101125932B1 (es) |
| CN (3) | CN103923169B (es) |
| AR (1) | AR064809A1 (es) |
| AU (1) | AU2007330478B2 (es) |
| CA (1) | CA2669849C (es) |
| CL (1) | CL2007003491A1 (es) |
| DK (1) | DK2091910T3 (es) |
| ES (1) | ES2524021T3 (es) |
| HK (3) | HK1138567A1 (es) |
| HN (1) | HN2007000536A (es) |
| IL (1) | IL198732A (es) |
| MX (1) | MX2009006055A (es) |
| NO (1) | NO338908B1 (es) |
| PA (1) | PA8759501A1 (es) |
| PE (1) | PE20081251A1 (es) |
| PL (1) | PL2091910T3 (es) |
| PT (1) | PT2091910E (es) |
| TW (1) | TWI345466B (es) |
| UY (1) | UY30758A1 (es) |
| WO (1) | WO2008068615A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4166558A1 (en) * | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| JP6564796B2 (ja) * | 2014-03-14 | 2019-08-21 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療活性化合物の医薬組成物 |
| CN106470679A (zh) | 2014-05-12 | 2017-03-01 | 科内图斯医药公司 | 用半胱天冬酶抑制剂治疗慢性肝脏疾病并发症 |
| BR112017003421B1 (pt) * | 2014-09-08 | 2023-10-10 | Pfizer Inc | Formas sólidas cristalinas de 6-carbóxi-2-(3,5-dicloro-fenil)- benzoxazol e composição farmacêutica |
| CA2975048C (en) * | 2015-01-30 | 2024-01-02 | Biomed Valley Discoveries, Inc. | Crystalline forms of c21h22ci2n4o2 |
| WO2016144830A1 (en) | 2015-03-06 | 2016-09-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| CN105017061B (zh) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | 一种恩利卡生的合成方法 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| KR20180101418A (ko) | 2015-12-31 | 2018-09-12 | 코나터스 파마슈티칼스, 인크. | 간 질환의 치료에서의 카스파제 억제제의 사용 방법 |
| CN109789119A (zh) | 2016-10-05 | 2019-05-21 | 诺华股份有限公司 | 用于治疗或预防纤维化、硬化疾病或障碍的含fxr激动剂的复合组合物 |
| US11434212B2 (en) | 2017-01-23 | 2022-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicyclic compound as a caspase inhibitor |
| JP2019514862A (ja) * | 2017-03-23 | 2019-06-06 | ノバルティス アーゲー | （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形 |
| AU2018246255B2 (en) * | 2017-03-30 | 2021-07-08 | Merck Patent Gmbh | Crystalline form of (s)-(2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl)-(6-methoxy-pyridazin-3-yl)-methanol |
| AR114251A1 (es) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida |
| EP3814327A1 (en) | 2018-06-29 | 2021-05-05 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| SG11202109700PA (en) | 2019-03-07 | 2021-10-28 | Conatus Pharmaceuticals Inc | Caspase inhibitors and methods of use thereof |
| CN111351780A (zh) * | 2019-12-29 | 2020-06-30 | 中船重工（邯郸）派瑞特种气体有限公司 | 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE149483T1 (de) * | 1991-07-30 | 1997-03-15 | Ajinomoto Kk | Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung |
| EP0625504B1 (de) * | 1993-05-12 | 1997-08-27 | HEUMANN PHARMA GmbH | Stabile und kristalline Form von Bezafibrat |
| US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
| CA2469882C (en) * | 2001-12-11 | 2009-09-29 | Kazuo Orita | Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same |
| AU2006267976B2 (en) * | 2005-07-11 | 2009-12-24 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
-
2007
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-03 PL PL07859033T patent/PL2091910T3/pl unknown
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/ja active Active
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/zh not_active Expired - Fee Related
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en active Active
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/es active Active
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/zh active Active
- 2007-12-03 PT PT78590338T patent/PT2091910E/pt unknown
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/es active IP Right Grant
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/zh active Active
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/ko active IP Right Grant
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/es unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/es not_active Application Discontinuation
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/es unknown
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/es unknown
- 2007-12-05 TW TW096146304A patent/TWI345466B/zh active
- 2007-12-05 AR ARP070105447A patent/AR064809A1/es not_active Application Discontinuation
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/es not_active Application Discontinuation
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/no not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/xx not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/xx unknown
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064809A1 (es) | Formas cristalinas | |
| AR112227A2 (es) | Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma | |
| AR054777A1 (es) | Modificaciones cristalinas de piraclostrobina | |
| ECSP12012147A (es) | Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales | |
| ECSP088859A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| EA201100794A1 (ru) | Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак | |
| UY31239A1 (es) | Sulfonamidas como moduladores de trpm8 | |
| ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
| ECSP066375A (es) | Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| UY31260A1 (es) | Compuestos de pirazol, composiciones conteniendolos y aplicaciones. | |
| EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
| ECSP10010722A (es) | Compuestos orgánicos | |
| EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
| EA201101330A1 (ru) | Замещенные пиримидины, предназначенные для лечения рака | |
| DE602008000754D1 (de) | Tropanverbindungen | |
| BRPI0603074A (pt) | forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a | |
| AR059596A1 (es) | Formas cristalinas anhidras y solvatadas de n-(benzo[b]tien-3-ilmetil)sulfamida. | |
| ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| TR201900371T4 (tr) | Alkilamin türevi. | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |